Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Oncoimmunology. 2014 Dec 13. doi: 10.4161/21624011.2014.955691. pii: 955691. pmc: PMC4292729
    Consensus guidelines for the detection of immunogenic cell death.
    Kepp O1,  Senovilla L2,  Vitale I3,  Vacchelli E4,  Adjemian S5,  Agostinis P6,  Apetoh L7,  Aranda F8,  Barnaba V9,  Bloy N10,  Bracci L11,  Breckpot K12,  Brough D13,  Buqué A14,  Castro MG15,  Cirone M16,  Colombo MI17,  Cremer I18,  Demaria S19,  Dini L20,  Eliopoulos AG21,  Faggioni A22,  Formenti SC23,  Fučíková J24,  Gabriele L25,  Gaipl US26,  Galon J27,  Garg A28,  Ghiringhelli F29,  Giese NA30,  Guo ZS31,  Hemminki A32,  Herrmann M33,  Hodge JW34,  Holdenrieder S35,  Honeychurch J36,  Hu HM37,  Huang X38,  Illidge TM39,  Kono K40,  Korbelik M41,  Krysko DV42,  Loi S43,  Lowenstein PR44,  Lugli E45,  Ma Y46,  Madeo F47,  Manfredi AA48,  Martins I49,  Mavilio D50,  Menger L51,  Merendino N52,  Michaud M53,  Mignot G54,  Mossman KL55,  Multhoff G56,  Oehler R57,  Palombo F58,  Panaretakis T59,  Pol J60,  Proietti E61,  Ricci JE62,  Riganti C63,  Rovere-Querini P64,  Rubartelli A65,  Sistigu A66,  Smyth MJ67,  Sonnemann J68,  Spisek R69,  Stagg J70,  Sukkurwala AQ71,  Tartour E72,  Thorburn A73,  Thorne SH74,  Vandenabeele P75,  Velotti F76,  Workenhe ST77,  Yang H78,  Zong WX79,  Zitvogel L80,  Kroemer G81,  Galluzzi L82
    Author information
    1Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
    2INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1015 ; Villejuif, France.
    3Regina Elena National Cancer Institute ; Rome, Italy.
    4Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    5Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Molecular Cell Biology Laboratory; Department of Immunology; Institute of Biomedical Sciences; University of São Paulo ; São Paulo, Brazil.
    6Cell Death Research and Therapy (CDRT) Laboratory; Department of Cellular and Molecular Medicine; University of Leuven ; Leuven, Belgium.
    7INSERM; UMR866 ; Dijon, France ; Centre Georges François Leclerc ; Dijon, France ; Université de Bourgogne ; Dijon, France.
    8Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    9Departement of Internal Medicine and Medical Sciences; University of Rome La Sapienza ; Rome, Italy ; Istituto Pasteur; Fondazione Cenci Bolognetti ; Rome, Italy.
    10Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    11Department of Hematology; Oncology and Molecular Medicine; Istituto Superiore di Sanità (ISS) ; Rome, Italy.
    12Laboratory of Molecular and Cellular Therapy (LMCT); Department of Biomedical Sciences Medical School of the Free University of Brussels (VUB) ; Jette, Belgium.
    13Faculty of Life Sciences; University of Manchester ; Manchester, UK.
    14Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    15Department of Neurosurgery and Cell and Developmental Biology; University of Michigan School of Medicine ; Ann Arbor, MI USA.
    16Department of Experimental Medicine; University of Rome La Sapienza ; Rome, Italy.
    17Laboratorio de Biología Celular y Molecular; Instituto de Histología y Embriología (IHEM); Facultad de Ciencias Médicas; Universidad Nacional de Cuyo; CONICET ; Mendoza, Argentina.
    18INSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Equipe 13; Center de Recherche des Cordeliers ; Paris, France.
    19Department of Pathology; New York University School of Medicine ; New York, NY USA.
    20Department of Biological and Environmental Science and Technology (DiSTeBA); University of Salento ; Lecce, Italy.
    21Molecular and Cellular Biology Laboratory; Division of Basic Sciences; University of Crete Medical School ; Heraklion, Greece ; Institute of Molecular Biology and Biotechnology; Foundation of Research and Technology - Hellas ; Heraklion, Greece.
    22Department of Experimental Medicine; University of Rome La Sapienza ; Rome, Italy.
    23Department of Radiation Oncology; NewYork University School of Medicine and Langone Medical Center ; New York, NY USA.
    24Department of Immunology; 2nd Faculty of Medicine and University Hospital Motol, Charles University ; Prague, Czech Republic ; Sotio ; Prague, Czech Republic.
    25Department of Hematology; Oncology and Molecular Medicine; Istituto Superiore di Sanità (ISS) ; Rome, Italy.
    26Department of Radiation Oncology; University Hospital Erlangen; University of Erlangen-Nürnberg ; Erlangen, Germany.
    27INSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Laboratory of Integrative Cancer Immunology; Center de Recherche des Cordeliers ; Paris, France.
    28Cell Death Research and Therapy (CDRT) Laboratory; Department of Cellular and Molecular Medicine; University of Leuven ; Leuven, Belgium.
    29INSERM; UMR866 ; Dijon, France ; Centre Georges François Leclerc ; Dijon, France ; Université de Bourgogne ; Dijon, France.
    30European Pancreas Center; Department of Surgery; University Hospital Heidelberg ; Heidelberg, Germany.
    31Department of Surgery; University of Pittsburgh ; Pittsburgh, PA USA.
    32Cancer Gene Therapy Group; Transplantation laboratory; Haartman Institute; University of Helsinki ; Helsinki, Finland.
    33Department of Internal Medicine 3; University of Erlangen-Nuremberg ; Erlangen, Germany.
    34Laboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute (NCI), National Institutes of Health (NIH) ; Bethesda, MD USA.
    35Institute of Clinical Chemistry and Clinical Pharmacology; University Hospital Bonn ; Bonn, Germany.
    36Faculty of Medical and Human Sciences, Institute of Cancer Studies; Manchester Academic Health Sciences Center; University of Manchester ; Manchester, UK.
    37Cancer Research and Biotherapy Center; Second Affiliated Hospital of Southeast University ; Nanjing, China ; Laboratory of Cancer Immunobiology; Earle A. Chiles Research Institute; Providence Portland Medical Center ; Portland, OR USA.
    38Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
    39Faculty of Medical and Human Sciences, Institute of Cancer Studies; Manchester Academic Health Sciences Center; University of Manchester ; Manchester, UK.
    40Department of Surgery; National University of Singapore ; Singapore, Singapore ; Cancer Science Institute of Singapore; National University of Singapore ; Singapore, Singapore.
    41British Columbia Cancer Agency ; Vancouver, Canada.
    42VIB Inflammation Research Center ; Ghent, Belgium ; Department of Biomedical Molecular Biology; Ghent University ; Ghent, Belgium.
    43Division of Cancer Medicine and Division of Research; Peter MacCallum Cancer Center; East Melbourne ; Victoria, Australia.
    44Department of Neurosurgery and Cell and Developmental Biology; University of Michigan School of Medicine ; Ann Arbor, MI USA.
    45Unit of Clinical and Experimental Immunology; Humanitas Clinical and Research Center ; Milan, Italy ; Department of Medical Biotechnologies and Translational Medicine, University of Milan ; Rozzano, Italy.
    46Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    47Institute of Molecular Biosciences; University of Graz ; Graz, Austria.
    48University Vita-Salute San Raffaele ; Milano, Italy ; San Raffaele Scientific Institute ; Milano, Italy.
    49Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM, U1030 ; Villejuif, France ; Faculté de Médecine; Université Paris-Sud/Paris XI ; Kremlin-Bicêtre, France.
    50Unit of Clinical and Experimental Immunology; Humanitas Clinical and Research Center ; Milan, Italy ; Department of Medical Biotechnologies and Translational Medicine, University of Milan ; Rozzano, Italy.
    51Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Cancer Immunology Unit, Research Department of Haematology; University College London (UCL) Cancer Institute ; London, UK.
    52Department of Ecological and Biological Sciences (DEB), Tuscia University ; Viterbo, Italy.
    53Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    54Cellular and Molecular Immunology and Endocrinology , Oniris; Nantes, France.
    55Department of Pathology and Molecular Medicine; McMaster Immunology Research Center ; Hamilton, Canada ; Institute for Infectious Disease Research; McMaster University ; Hamilton, Canada.
    56Department of Radiation Oncology; Klinikum rechts der Isar; Technical University of Munich ; Munich, Germany.
    57Comprehensive Cancer Center; Medical University of Vienna ; Vienna, Austria.
    58Departement of Internal Medicine and Medical Sciences; University of Rome La Sapienza ; Rome, Italy ; Istituto Pasteur; Fondazione Cenci Bolognetti ; Rome, Italy.
    59Department of Oncology-Pathology; Karolinska Institute ; Stockholm, Sweden.
    60Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
    61Department of Hematology; Oncology and Molecular Medicine; Istituto Superiore di Sanità (ISS) ; Rome, Italy.
    62INSERM; U1065 ; Nice, France ; Equipe "Contrôle Métabolique des Morts Cellulaires," Center Méditerranéen de Médecine Moléculaire (C3M) ; Nice, France ; Faculté de Médecine; Université de Nice Sophia Antipolis ; Nice, France ; Centre Hospitalier Universitaire de Nice ; Nice, France.
    63Department of Oncology and Subalpine Center for Research and Experimental Medicine (CeRMS); University of Turin ; Turin, Italy.
    64University Vita-Salute San Raffaele ; Milano, Italy ; San Raffaele Scientific Institute ; Milano, Italy.
    65Cell Biology Unit; Azienda Ospedaliera Universitaria San Martino ; Istituto Nazionale per la Ricerca sul Cancro ; Genova, Italy.
    66Regina Elena National Cancer Institute ; Rome, Italy.
    67Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Herston, Australia ; School of Medicine, University of Queensland ; Herston, Australia.
    68Department of Pediatric Haematology and Oncology; Jena University Hospital, Children's Clinic ; Jena, Germany.
    69Department of Immunology; 2nd Faculty of Medicine and University Hospital Motol, Charles University ; Prague, Czech Republic ; Sotio ; Prague, Czech Republic.
    70Centre de Recherche du Center Hospitalier de l'Université de Montréal; Faculté de Pharmacie, Université de Montréal ; Montréal, Canada.
    71Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Department of Pathology, Dow International Medical College; Dow University of Health Sciences ; Karachi, Pakistan.
    72INSERM; U970 ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
    73Department of Pharmacology; University of Colorado School of Medicine ; Aurora, CO USA.
    74Department of Surgery; University of Pittsburgh ; Pittsburgh, PA USA.
    75VIB Inflammation Research Center ; Ghent, Belgium ; Department of Biomedical Molecular Biology; Ghent University ; Ghent, Belgium ; Methusalem Program; Ghent University ; Ghent, Belgium.
    76Department of Ecological and Biological Sciences (DEB), Tuscia University ; Viterbo, Italy.
    77Department of Pathology and Molecular Medicine; McMaster Immunology Research Center ; Hamilton, Canada ; Institute for Infectious Disease Research; McMaster University ; Hamilton, Canada.
    78University of Hawaii Cancer Center ; Honolulu, HI USA.
    79Department of Molecular Genetics and Microbiology; Stony Brook University ; Stony Brook, NY USA.
    80INSERM; U1015 ; Villejuif, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Centre d'Investigation Clinique Biothérapie 507 (CICBT507); Gustave Roussy Cancer Campus ; Villejuif, France.
    81Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
    82Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
    Abstract

    Apoptotic cells have long been considered as intrinsically tolerogenic or unable to elicit immune responses specific for dead cell-associated antigens. However, multiple stimuli can trigger a functionally peculiar type of apoptotic demise that does not go unnoticed by the adaptive arm of the immune system, which we named "immunogenic cell death" (ICD). ICD is preceded or accompanied by the emission of a series of immunostimulatory damage-associated molecular patterns (DAMPs) in a precise spatiotemporal configuration. Several anticancer agents that have been successfully employed in the clinic for decades, including various chemotherapeutics and radiotherapy, can elicit ICD. Moreover, defects in the components that underlie the capacity of the immune system to perceive cell death as immunogenic negatively influence disease outcome among cancer patients treated with ICD inducers. Thus, ICD has profound clinical and therapeutic implications. Unfortunately, the gold-standard approach to detect ICD relies on vaccination experiments involving immunocompetent murine models and syngeneic cancer cells, an approach that is incompatible with large screening campaigns. Here, we outline strategies conceived to detect surrogate markers of ICD in vitro and to screen large chemical libraries for putative ICD inducers, based on a high-content, high-throughput platform that we recently developed. Such a platform allows for the detection of multiple DAMPs, like cell surface-exposed calreticulin, extracellular ATP and high mobility group box 1 (HMGB1), and/or the processes that underlie their emission, such as endoplasmic reticulum stress, autophagy and necrotic plasma membrane permeabilization. We surmise that this technology will facilitate the development of next-generation anticancer regimens, which kill malignant cells and simultaneously convert them into a cancer-specific therapeutic vaccine.


    KEYWORDS: APC, antigen-presenting cell, ATF6, activating transcription factor 6, ATP release, BAK1, BCL2-antagonist/killer 1, BAX, BCL2-associated X protein, BCL2, B-cell CLL/lymphoma 2 protein, CALR, calreticulin, CTL, cytotoxic T lymphocyte, DAMP, damage-associated molecular pattern, DAPI, 4′,6-diamidino-2-phenylindole, DiOC6(3), 3,3′-dihexyloxacarbocyanine iodide, EIF2A, eukaryotic translation initiation factor 2A, ER, endoplasmic reticulum, FLT3LG, fms-related tyrosine kinase 3 ligand, G3BP1, GTPase activating protein (SH3 domain) binding protein 1, GFP, green fluorescent protein, H2B, histone 2B, HMGB1, HMGB1, high mobility group box 1, HSP, heat shock protein, HSV-1, herpes simplex virus type I, ICD, immunogenic cell death, IFN, interferon, IL, interleukin, MOMP, mitochondrial outer membrane permeabilization, PDIA3, protein disulfide isomerase family A, PI, propidium iodide, RFP, red fluorescent protein, TLR, Toll-like receptor, XBP1, X-box binding protein 1, autophagy, calreticulin, endoplasmic reticulum stress, immunotherapy, member 3, Δψm, mitochondrial transmembrane potential

    Publikations ID: 25941621
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt